<![CDATA[Novo Nordisk A/S - Press Releases]]><![CDATA[Novo Nordisk invests DKK 380 million in its Kalundborg plant]]><![CDATA[Novo Nordisk lancerer Tresiba® (insulin degludec) i Danmark]]><![CDATA[Novo Nordisk launches NovoSeven® with pre-filled syringe for fast bleeding control]]><![CDATA[Tresiba® now ready to be launched in Japan]]><![CDATA[Novo Nordisk publishes its 2012 Annual Report]]><![CDATA[Novo Nordisk upgraded to ‘A1’ by Moody’s]]><![CDATA[Novo Nordisk to create the world's first all-diabetes professional cycling team]]><![CDATA[Families carry a major burden of the diabetes pandemic, according to new results from global study]]><![CDATA[Data show patients with type 2 diabetes are likelier to reach HbA1c target below 7% during 26 weeks treatment with Victoza(R) (liraglutide) compared with sitagliptin or exenatide BID]]><![CDATA[Novo Nordisk ranked among the top 25 Best Multinational Workplaces]]><![CDATA[Novo Nordisk files for regulatory approval of turoctocog alfa for haemophilia A in the US and EU]]><![CDATA[New data from a global survey find four in five people with type 2 diabetes have experienced hypoglycaemia, affecting their diabetes management]]><![CDATA[New analysis shows Victoza® (liraglutide) is more effective when used early in the management of type 2 diabetes]]><![CDATA[Investigational insulin degludec shows 43% lower rates of night-time hypoglycaemia than insulin glargine in a 2-year study investigating 1,030 people with type 2 diabetes who had not previously used insulin]]><![CDATA[Novo Nordisk invests further in China by opening new, bigger research and development centre]]><![CDATA[Novo Nordisk ranks 4th among the world’s top 20 science employers]]><![CDATA[Global study finds people with haemophilia fight challenges in their professional career but succeed in completing education and getting a job]]><![CDATA[JDRF and Novo Nordisk establish R&D collaboration in type 1 diabetes]]><![CDATA[Global survey finds one in four type 2 diabetes patients do not take basal insulin as prescribed and more than a third suffer from hypoglycaemia]]><![CDATA[A new study with 'real world' data shows greater efficacy of Victoza(R), with weight loss and cost-effectiveness, in type 2 diabetes compared to twice-daily exenatide and DPP-4 inhibitors]]>